CytoDyn Inc.

For the period ended Aug 31, 2026. Filed Oct 14, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Aug 31, 2026 · Filed Oct 14, 2026

CYDYStored price and day change unavailable

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Cover page Table of Contents

PART I Financial Information

ITEM 1. CONSOLIDATED FINANCIAL STATEMENTS (no text here)

Item 1. Consolidated Financial Statements ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK (no text here)

Item 3. Quantitative and Qualitative Disclosures about Market Risk

ITEM 4. CONTROLS AND PROCEDURES (no text here)

Item 4. Controls and Procedures

PART II Other Information

ITEM 1. LEGAL PROCEEDINGS (no text here)

Item 1. Legal Proceedings

ITEM 1A. RISK FACTORS (no text here)

Item 1A. Risk Factors

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS (no text here)

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds ITEM 6. EXHIBITS

Item 1. Legal Proceedings

For a description of pending material legal proceedings, please see Note 10, Commitments and Contingencies–Legal Proceedings, of the Notes to Consolidated Financial Statements included in Part I, Item 1 of this Form 10-Q.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.